Why Your Body Destroys NAD+ Before It Can Use It (And the $5 Fix Nobody Talks About)

Your body cannot absorb NAD+ directly. That is the starting point for understanding everything that follows, because once you know that, the entire supplement market starts to look very different.

NAD+ is a large molecule, and large molecules cannot cross cell membranes on their own. So your body breaks it down outside the cell, transports the smaller pieces through the membrane, and then reassembles them into NAD+ on the inside. That reassembly process is called the salvage pathway, and it is the central mechanism behind almost every NAD+ supplement being sold today.

Here is where the map matters. When you take NMN or NR as a supplement, people assume those molecules travel directly into your cells and get converted there. The reality is more complicated. NMN cannot enter cells directly either. A 2016 study found that NMN must first be converted to NR by an enzyme called CD73 before it can cross the cell membrane, which means NMN and NR both end up in the same place, waiting to enter through the same door. They funnel through the same pathway. So if you are paying more for NMN because you think it skips a step that NR takes, it does not.

And this matters even more when you understand what IV NAD+ does, because IV is often sold as the purest, most direct delivery method. A 2019 pilot study tracked what happened to IV NAD+ in real time during a 750 milligram infusion and found that the NAD+ was completely removed from plasma and broken down before it could enter any cells. All of it. The body degraded 100 percent of the NAD+ in the bloodstream before it reached its destination, and cells then absorbed the breakdown products and ran them through the salvage pathway to rebuild NAD+ from scratch. IV delivery does not bypass the process. It just delivers the starting material in a different form.

So everything runs through this one pathway, and that would be fine if the pathway were not getting increasingly compromised as you get older.

The enzyme that becomes the problem here is called CD38, which is a protein that breaks down NAD+ and uses its components for cell signaling. CD38 is not a villain exactly, it serves real biological functions, but the issue is that it becomes dramatically more active with age. A 2016 study found that CD38 activity increases two to three fold across tissues as organisms age, and that this increase correlates almost perfectly with the decline in NAD+ levels seen in aging. Think of it like a drain in a bathtub that gets wider as you get older. The salvage pathway is still filling the tub, but the drain is removing NAD+ faster than the pathway can replace it, and the gap widens every decade.

This is the context that makes the niacin finding actually significant.

Your body has a second, completely separate route to make NAD+ that does not touch the salvage pathway at all. It is called the Preiss-Handler pathway, named after the researchers who mapped it, and it is activated by nicotinic acid, which is the form of vitamin B3 most people know as niacin. The Preiss-Handler pathway runs parallel to the salvage pathway and produces NAD+ through a different sequence of enzymes. CD38 still degrades NAD+ once it is made, but the production process itself bypasses the congested salvage pathway entirely.

A 2020 study tested this directly in a population with confirmed systemic NAD+ deficiency. These were patients with adult-onset mitochondrial myopathy, a condition that produces measurable, documented low NAD+ levels, which made it a clean test of whether niacin could actually move the needle on real deficiency rather than just healthy people with normal levels. The patients took niacin at doses between 750 and 1000 milligrams per day. After ten months, blood NAD+ had risen 2.3 times above baseline. Muscle NAD+ rose 1.3 times. Muscle strength improved. Markers of mitochondrial biogenesis increased. The Preiss-Handler pathway, activated by a molecule that costs roughly five dollars a month at any pharmacy, produced results in the same range as what NMN and NR trials report.

There is one thing that comes up consistently when people try niacin, and it is worth addressing directly rather than burying. Niacin causes a flush. Your skin turns red, feels warm, sometimes itches or tingles, usually in the face, neck, and chest. This happens because niacin triggers a release of prostaglandins, which are compounds that cause blood vessels near the skin to dilate. It is not an allergic reaction and it is not harmful. It typically lasts twenty to thirty minutes and diminishes significantly after the first one to two weeks of consistent use as your body adjusts. Starting with a lower dose and taking niacin with food tends to reduce the intensity. It is the primary reason niacin fell out of favor compared to the non-flushing versions like nicotinamide, but nicotinamide does not activate the Preiss-Handler pathway the same way and has shown different metabolic effects. The flush is the trade-off for the pathway you actually want.

There is also something worth noting about what NR does in the body, because it complicates the clean NMN versus NR story that gets told in marketing. A 2019 human study found that when people took NR, the body produced significant amounts of something called NAAD, which is an intermediate in the Preiss-Handler pathway, not the salvage pathway. This means some of the NR you take is actually being converted to nicotinic acid in the body and then processed through the Preiss-Handler route anyway. The pathways are not as separate in practice as they are in diagrams. The body is routing precursors where it needs them.

The practical conclusion is simpler than the biochemistry. If your goal is raising NAD+ and you are not dealing with a condition that specifically requires a particular precursor, niacin activates a separate production pathway that the expensive supplements do not use, costs a fraction of the price, and produced results in a range comparable to those supplements in human trials. The flush is real, it is temporary, and it is the only meaningful barrier.

What makes this worth understanding at the system level is that the supplement industry's version of this story ends at the salvage pathway, because that is where the expensive products live. The biology does not end there. Your body built a second road to the same destination, and nobody is selling it because the margin on a five dollar bottle of niacin does not fund a marketing campaign.

---

References

1. Ratajczak J, Joffraud M, Trammell SAJ, et al. 2016. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nature Communications, 7:13103. Finding: NMN must be converted to NR by CD73 before cellular uptake, establishing NR as the common entry point for both NMN and NR supplementation. Source
2. Elhassan YS, Kluckova K, Fletcher RS, et al. 2019. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports, 287:1717-1728. Finding: NR supplementation produced significant increases in NAAD a Preiss-Handler pathway intermediate in human muscle, indicating NR partially converts to nicotinic acid in vivo. Source
3. Pirinen E, Auranen M, Khan NA, et al. 2020. Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metabolism, 316:1078-1090. Finding: Niacin 750-1000 mg/day raised blood NAD+ 2.3x and muscle NAD+ 1.3x in human subjects via the Preiss-Handler pathway, with concurrent improvements in muscle strength and mitochondrial biogenesis. Source
4. Grant R, Berg J, Mestayer R, et al. 2019. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Frontiers in Aging Neuroscience, 11:257. Finding: IV NAD+ 750 mg was rapidly and completely removed from plasma, with metabolites confirming full extracellular degradation before cellular uptake. Source
5. Camacho-Pereira J, Tarrago MG, Chini CCS, et al. 2016. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 236:1127-1139. Finding: CD38 activity increases 2-3 fold with age across tissues, with near-perfect inverse correlation to NAD+ levels. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness